SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer

Y.Munemotoa, M.Nakamurab, M.Takahashic, M.Kotakad, H.Kurodae T.Katofg, N.Minagawah, S.Nourai, M.Fukunagaj, H.Kuramochik, T.Touyamal, T.Takahashim, K.Miwan, H.Satakeop, S.Kurosawaq, T.Miuraq, H.Mishimar, J.Sakamotos, N.Nagatae

European Journal of Cancer Volume 119, September 2019, Pages 158-167